Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma · Source last updated 2026-08-04
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 2 years
What was measured
Only adverse events that are possibly, probably or definitely related to study drug are reported.
Groups in this outcome
Arm I (Chemotherapy, Nivolumab, Radiation)
Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and nivolumab IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Arm I (Chemotherapy, Nivolumab, Radiation)
481
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
476
Reported measurements
Abdominal distension
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Abdominal pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
61
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
110
Not reported
Not reported
Not reported
Not reported
Activated partial thromboplastin time prolonged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Acute kidney injury
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Adrenal insufficiency
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Agitation
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Akathisia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Alanine aminotransferase increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
163
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
209
Not reported
Not reported
Not reported
Not reported
Alkaline phosphatase increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
58
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
84
Not reported
Not reported
Not reported
Not reported
Allergic reaction
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Allergic rhinitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Alopecia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
103
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
127
Not reported
Not reported
Not reported
Not reported
Amenorrhea
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
5
Not reported
Not reported
Not reported
Not reported
Amnesia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Anal fissure
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Anal fistula
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Anal hemorrhage
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Anemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
198
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
222
Not reported
Not reported
Not reported
Not reported
Anorectal infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Anorexia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
61
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
107
Not reported
Not reported
Not reported
Not reported
Anosmia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Anxiety
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
20
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
30
Not reported
Not reported
Not reported
Not reported
Appendicitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arthralgia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
65
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
60
Not reported
Not reported
Not reported
Not reported
Arthritis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Ascites
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Aspartate aminotransferase increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
129
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
168
Not reported
Not reported
Not reported
Not reported
Ataxia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Atelectasis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Atrial fibrillation
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Autoimmune disorder
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Back pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
27
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
35
Not reported
Not reported
Not reported
Not reported
Bacteremia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Belching
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Bladder infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Bloating
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
7
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
18
Not reported
Not reported
Not reported
Not reported
Blood and lymphatic system disorders - Other, spec
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
5
Not reported
Not reported
Not reported
Not reported
Blood bicarbonate decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
5
Not reported
Not reported
Not reported
Not reported
Blood bilirubin increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
14
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
14
Not reported
Not reported
Not reported
Not reported
Blood lactate dehydrogenase increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
18
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
25
Not reported
Not reported
Not reported
Not reported
Blurred vision
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
11
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
15
Not reported
Not reported
Not reported
Not reported
Bone pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
41
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
99
Not reported
Not reported
Not reported
Not reported
Brachial plexopathy
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Breast pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Bronchial infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Bronchospasm
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Bruising
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
8
Not reported
Not reported
Not reported
Not reported
Bullous dermatitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Burn
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Buttock pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
CD4 lymphocytes decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
CPK increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Cardiac arrest
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Cardiac disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Cardiac troponin I increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Cardiac troponin T increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Catheter related infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Cheilitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Chest pain - cardiac
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Chest wall pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Chills
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
22
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
20
Not reported
Not reported
Not reported
Not reported
Cholesterol high
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Chronic kidney disease
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Cognitive disturbance
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Colitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Colonic obstruction
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Concentration impairment
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
7
Not reported
Not reported
Not reported
Not reported
Confusion
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Conjunctivitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Conjunctivitis infective
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Constipation
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
196
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
209
Not reported
Not reported
Not reported
Not reported
Cough
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
33
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
32
Not reported
Not reported
Not reported
Not reported
Creatinine increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
27
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
13
Not reported
Not reported
Not reported
Not reported
Cyanosis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Dehydration
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
14
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
32
Not reported
Not reported
Not reported
Not reported
Delirium
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Depressed level of consciousness
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Depression
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
10
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
10
Not reported
Not reported
Not reported
Not reported
Dermatitis radiation
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Diarrhea
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
101
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
130
Not reported
Not reported
Not reported
Not reported
Disseminated intravascular coagulation
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Dizziness
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
29
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
40
Not reported
Not reported
Not reported
Not reported
Dry eye
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Dry mouth
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
19
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
32
Not reported
Not reported
Not reported
Not reported
Dry skin
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
15
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
17
Not reported
Not reported
Not reported
Not reported
Dysarthria
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Dysesthesia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Dysgeusia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
37
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
60
Not reported
Not reported
Not reported
Not reported
Dysmenorrhea
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Dyspepsia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
34
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
21
Not reported
Not reported
Not reported
Not reported
Dysphagia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
8
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
7
Not reported
Not reported
Not reported
Not reported
Dysphasia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Dyspnea
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
43
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
58
Not reported
Not reported
Not reported
Not reported
Dysuria
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Ear and labyrinth disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Ear pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Eczema
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
7
Not reported
Not reported
Not reported
Not reported
Edema face
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
5
Not reported
Not reported
Not reported
Not reported
Edema limbs
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
17
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
17
Not reported
Not reported
Not reported
Not reported
Ejection fraction decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Electrocardiogram QT corrected interval prolonged
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Electrocardiogram T wave abnormal
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Endocrine disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
9
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Enterocolitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Enterocolitis infectious
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Eosinophilia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
12
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
16
Not reported
Not reported
Not reported
Not reported
Epistaxis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
10
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
16
Not reported
Not reported
Not reported
Not reported
Erectile dysfunction
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Erythema multiforme
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Erythroderma
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Esophageal pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Esophagitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Extrapyramidal disorder
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Eye disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Facial muscle weakness
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Facial pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Fall
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
5
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
9
Not reported
Not reported
Not reported
Not reported
Fatigue
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
232
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
246
Not reported
Not reported
Not reported
Not reported
Febrile neutropenia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
28
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
33
Not reported
Not reported
Not reported
Not reported
Fecal incontinence
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Fever
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
64
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
63
Not reported
Not reported
Not reported
Not reported
Fibrinogen decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Flank pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Flashing lights
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Flatulence
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Floaters
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Flu like symptoms
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Flushing
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
10
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Folliculitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Fracture
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
GGT increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Gait disturbance
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Gastric hemorrhage
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Gastritis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
9
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
8
Not reported
Not reported
Not reported
Not reported
Gastroesophageal reflux disease
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
27
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
40
Not reported
Not reported
Not reported
Not reported
Gastrointestinal disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
10
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
14
Not reported
Not reported
Not reported
Not reported
Gastrointestinal pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Gastroparesis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
General disorders and administration site conditio
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
7
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Generalized edema
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Generalized muscle weakness
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
16
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
25
Not reported
Not reported
Not reported
Not reported
Glucose intolerance
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Glucosuria
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Guillain-Barre syndrome
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Gynecomastia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Headache
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
71
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
77
Not reported
Not reported
Not reported
Not reported
Heart failure
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Hematuria
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Hemolysis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Hemorrhoidal hemorrhage
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Hemorrhoids
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Hepatic failure
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Hepatobiliary disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Herpes simplex reactivation
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Hiccups
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
11
Not reported
Not reported
Not reported
Not reported
Hoarseness
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Hot flashes
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
9
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
20
Not reported
Not reported
Not reported
Not reported
Hypercalcemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
10
Not reported
Not reported
Not reported
Not reported
Hyperglycemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
57
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
67
Not reported
Not reported
Not reported
Not reported
Hyperhidrosis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
14
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
16
Not reported
Not reported
Not reported
Not reported
Hyperkalemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
5
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Hyperlipidemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Hypermagnesemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Hypernatremia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
5
Not reported
Not reported
Not reported
Not reported
Hyperphosphatemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
17
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
16
Not reported
Not reported
Not reported
Not reported
Hypertension
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
41
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
43
Not reported
Not reported
Not reported
Not reported
Hyperthyroidism
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
13
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Hypertriglyceridemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Hyperuricemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
9
Not reported
Not reported
Not reported
Not reported
Hypoalbuminemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
43
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
41
Not reported
Not reported
Not reported
Not reported
Hypocalcemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
34
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
35
Not reported
Not reported
Not reported
Not reported
Hypoglycemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
7
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Hypokalemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
31
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
64
Not reported
Not reported
Not reported
Not reported
Hypomagnesemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
5
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
22
Not reported
Not reported
Not reported
Not reported
Hyponatremia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
30
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
57
Not reported
Not reported
Not reported
Not reported
Hypoparathyroidism
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Hypophosphatemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
11
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
19
Not reported
Not reported
Not reported
Not reported
Hypotension
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
18
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
18
Not reported
Not reported
Not reported
Not reported
Hypothyroidism
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
36
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Hypoxia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
INR increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Ileus
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Immune system disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Infections and infestations - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
18
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
12
Not reported
Not reported
Not reported
Not reported
Infusion related reaction
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
36
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
10
Not reported
Not reported
Not reported
Not reported
Infusion site extravasation
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Injection site reaction
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Injury, poisoning and procedural complications - O
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Insomnia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
30
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
54
Not reported
Not reported
Not reported
Not reported
Investigations - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
13
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
10
Not reported
Not reported
Not reported
Not reported
Irregular menstruation
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
5
Not reported
Not reported
Not reported
Not reported
Irritability
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Joint range of motion decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Laryngopharyngeal dysesthesia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Lethargy
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Leukocytosis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Libido decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Lip infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Lipase increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Localized edema
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Lung infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
10
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
14
Not reported
Not reported
Not reported
Not reported
Lymph gland infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Lymph node pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Lymphocyte count decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
109
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
114
Not reported
Not reported
Not reported
Not reported
Lymphocyte count increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
10
Not reported
Not reported
Not reported
Not reported
Malaise
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
8
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Memory impairment
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
8
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Menorrhagia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Metabolism and nutrition disorders - Other, specif
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
5
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Mitral valve disease
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Movements involuntary
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Mucosal infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Mucositis oral
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
109
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
100
Not reported
Not reported
Not reported
Not reported
Muscle cramp
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
14
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
19
Not reported
Not reported
Not reported
Not reported
Muscle weakness lower limb
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
5
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
7
Not reported
Not reported
Not reported
Not reported
Muscle weakness trunk
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Muscle weakness upper limb
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Musculoskeletal and connective tissue disorder -
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
5
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Myalgia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
54
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
58
Not reported
Not reported
Not reported
Not reported
Myositis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Nail changes
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
9
Not reported
Not reported
Not reported
Not reported
Nail discoloration
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
7
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
16
Not reported
Not reported
Not reported
Not reported
Nail infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Nail ridging
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Nasal congestion
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
12
Not reported
Not reported
Not reported
Not reported
Nausea
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
317
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
331
Not reported
Not reported
Not reported
Not reported
Neck edema
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Neck pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Neoplasms benign, malignant and unspecified (incl
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Nervous system disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
5
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
8
Not reported
Not reported
Not reported
Not reported
Neuralgia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Neutrophil count decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
275
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
166
Not reported
Not reported
Not reported
Not reported
Non-cardiac chest pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
16
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
16
Not reported
Not reported
Not reported
Not reported
Oral dysesthesia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Oral hemorrhage
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Oral pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
30
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
24
Not reported
Not reported
Not reported
Not reported
Pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
43
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
31
Not reported
Not reported
Not reported
Not reported
Pain in extremity
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
22
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
36
Not reported
Not reported
Not reported
Not reported
Palmar-plantar erythrodysesthesia syndrome
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Palpitations
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
7
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Pancreatic enzymes decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Pancreatitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Papulopustular rash
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Paresthesia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
36
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
43
Not reported
Not reported
Not reported
Not reported
Paronychia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Paroxysmal atrial tachycardia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Pelvic pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Penile infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Pericardial effusion
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Pericarditis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Peripheral motor neuropathy
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
21
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
36
Not reported
Not reported
Not reported
Not reported
Peripheral sensory neuropathy
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
141
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
268
Not reported
Not reported
Not reported
Not reported
Pharyngeal mucositis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Pharyngitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Phlebitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Photophobia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Photosensitivity
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Platelet count decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
53
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
89
Not reported
Not reported
Not reported
Not reported
Pleural effusion
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Pleuritic pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Pneumonitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
11
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
15
Not reported
Not reported
Not reported
Not reported
Postnasal drip
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Presyncope
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Productive cough
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Proteinuria
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Pruritus
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
48
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
25
Not reported
Not reported
Not reported
Not reported
Psychiatric disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Psychosis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Pulmonary edema
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Rash acneiform
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
16
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
12
Not reported
Not reported
Not reported
Not reported
Rash maculo-papular
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
55
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
59
Not reported
Not reported
Not reported
Not reported
Rash pustular
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Rectal fissure
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Rectal hemorrhage
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Rectal pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Renal and urinary disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Respiratory failure
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Respiratory, thoracic and mediastinal disorders -
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Restrictive cardiomyopathy
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Rhabdomyolysis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Rhinorrhea
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
8
Not reported
Not reported
Not reported
Not reported
Salivary duct inflammation
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Scalp pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Scrotal pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Seizure
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Sepsis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
8
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
15
Not reported
Not reported
Not reported
Not reported
Serum amylase increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Sinus bradycardia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Sinus disorder
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Sinus tachycardia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
17
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
25
Not reported
Not reported
Not reported
Not reported
Skin and subcutaneous tissue disorders - Other, sp
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
16
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
18
Not reported
Not reported
Not reported
Not reported
Skin hyperpigmentation
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
8
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
8
Not reported
Not reported
Not reported
Not reported
Skin hypopigmentation
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Skin infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
10
Not reported
Not reported
Not reported
Not reported
Skin ulceration
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Small intestinal obstruction
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Sneezing
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Somnolence
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Sore throat
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
16
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
27
Not reported
Not reported
Not reported
Not reported
Spasticity
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Stomach pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
10
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
10
Not reported
Not reported
Not reported
Not reported
Stroke
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Superficial thrombophlebitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Supraventricular tachycardia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Syncope
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Tendon reflex decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Testicular pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Thromboembolic event
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
12
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
10
Not reported
Not reported
Not reported
Not reported
Thrush
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
7
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
14
Not reported
Not reported
Not reported
Not reported
Thyroid stimulating hormone increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
28
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Tinnitus
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
8
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
6
Not reported
Not reported
Not reported
Not reported
Tooth discoloration
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Tooth infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Toothache
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Tracheal mucositis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Tracheitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Tremor
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Tumor lysis syndrome
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Tumor pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Typhlitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Upper gastrointestinal hemorrhage
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Upper respiratory infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
7
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
8
Not reported
Not reported
Not reported
Not reported
Urinary frequency
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Urinary incontinence
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Urinary retention
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Urinary tract infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
7
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
12
Not reported
Not reported
Not reported
Not reported
Urinary tract pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Urinary urgency
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Urticaria
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Vaginal discharge
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Vaginal infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
4
Not reported
Not reported
Not reported
Not reported
Vascular access complication
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Vascular disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Vasovagal reaction
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Ventricular arrhythmia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Ventricular tachycardia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Vertigo
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Vision decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Voice alteration
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Vomiting
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
138
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
160
Not reported
Not reported
Not reported
Not reported
Watering eyes
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
5
Not reported
Not reported
Not reported
Not reported
Weight gain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
13
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
8
Not reported
Not reported
Not reported
Not reported
Weight loss
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
25
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
71
Not reported
Not reported
Not reported
Not reported
Wheezing
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
White blood cell decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
202
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
136
Not reported
Not reported
Not reported
Not reported
Wound infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Chemotherapy, Nivolumab, Radiation)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
1
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
3
title
Abdominal distension
categories
measurements
group Id
OG000
value
61
group Id
OG001
value
110
title
Abdominal pain
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
3
title
Activated partial thromboplastin time prolonged
categories
measurements
group Id
OG000
value
3
group Id
OG001
value
3
title
Acute kidney injury
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
0
title
Adrenal insufficiency
categories
measurements
group Id
OG000
value
4
group Id
OG001
value
0
title
Agitation
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
title
Akathisia
categories
measurements
group Id
OG000
value
163
group Id
OG001
value
209
title
Alanine aminotransferase increased
categories
measurements
group Id
OG000
value
58
group Id
OG001
value
84
title
Alkaline phosphatase increased
categories
measurements
group Id
OG000
value
4
group Id
OG001
value
6
title
Allergic reaction
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
3
title
Allergic rhinitis
categories
measurements
group Id
OG000
value
103
group Id
OG001
value
127
title
Alopecia
denoms
counts
group Id
OG000
value
481
group Id
OG001
value
476
units
Participants
description
Only adverse events that are possibly, probably or definitely related to study drug are reported.
groups
description
Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and nivolumab IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.
id
OG000
title
Arm I (Chemotherapy, Nivolumab, Radiation)
description
Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.
id
OG001
title
Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)
Triangle